Privacy

Cookie Policy

Contact

Home

ABOUT

Editorial

PRESS RELEASES

MEDICAL DEVICE NEWS MAGAZINE

A DIGITAL PUBLICATION FOR THE PRACTICING MEDICAL SPECIALIST, INDUSTRY EXECUTIVE AND INVESTOR

SUBSCRIBE

Market Reports

FDA

Executives

Funding

Non Profits

Hospitals

Acquisitions

Health

Biotechnology News Magazine

STALIF C-Ti® Study Published Journal of Surgery & Anesthesia Research

Supports Clinical Effectiveness of Centinel Spine's STALIF® Integrated Interbody™ System

Centinel Spine®, LLC, announced the recent publication of a research study on its STALIF C-Ti® product in the Journal of Surgery & Anesthesia Research: “Preliminary 12-Month Safety and Efficacy Outcomes for the Treatment of Cervical Radiculopathy and Myelopathy with the Stalif-C Integrated Interbody Fusion Device.”1

The prospective multi-center study supports that patients receiving STALIF C-Ti implants demonstrated significant improvements in clinical outcome scores with minimal overall complication rate.

he clinical study utilizing the STALIF C-Ti integrated cage-screw implants was performed in 145 patients and 12-month outcome scores demonstrated significant improvement in all available patient reported outcome scores collected (p<0.05 for all), including NDI, VAS neck, VAS left arm, and VAS right arm.

Co-investigator on the study Jad G. Khalil, MD of Michigan Orthopaedic Surgeons commented, “This is what I believe to be a very important multi-center study on stand-alone devices. There is very little data on stand-alone devices. And, while reference is frequently made comparing cervical fusions, the majority of those references are comparing plated fusions. This study was undertaken to determine if there was an advantage to an Integrated Interbody device over traditional plated fusion. The study was conducted at eleven centers across the country—a mix of private practice and university-based programs, with all data collected and entered into a validated database.” Dr. Khalil concluded, “I believe this study will be very important in influencing fusion device selection and is long overdue.”

Centinel Spine’s CEO, Steve Murray, stated, “We are committed to providing clinical evidence to support our portfolio of devices and this study is one of the few multi-center prospective clinical evaluations of this type of technology. We are dedicated to advancing evidence that further supports the stand-alone fusion platform that was pioneered by Centinel Spine.”

The STALIF C-Ti implant technology has been engineered based on the STALIF design, which has a history of over 30 years of clinical usage and has helped thousands of patients regain their lives. STALIF implants provide compressive fixation at the fusion site, pulling the vertebral bodies onto the implant and graft material to enhance opportunities for fusion in line with Wolff’s Law of Bone Healing.


1 Barrett Boody, Jad Khalil, Betsy Grunch, Michael Musacchio, Amir Vokshoor, et al (2021) Preliminary 12-Month Safety and Efficacy Outcomes for the Treatment of Cervical Radiculopathy and Myelopathy with the Stalif-C Integrated Interbody Fusion Device. Journal of Surgery & Anesthesia Research. SRC/JSAR-133. DOI: https://doi.org/10.47363/JSAR/2021(2)128

Other News

HypnoVR Raises €4.5 Million

The funds will allow HypnoVR to accelerate the commercial roll-out of its virtual reality-based medical hypnosis solution in France and globally. The company will also be stepping up efforts in its award-winning R&D program in order to further increase the therapeutic efficacy of its solution and broaden its scope of application to other medical and paramedical fields. 

Fluidx Medical Technology Announces Series A Led by Multinational Strategic Investor

Fluidx Medical Technology, a privately held medical device company founded to develop GPX, an innovative embolic material, and other technologies today announced the oversubscribed...

Trajan Group Acquires Axel Semrau GmbH

Trajan's automation business and Axel Semrau have worked in close cooperation for several years.

Alpheus Medical Closes $16M In Series A Financing For Novel Glioma Brain Cancer Treatment

Funds to support first-in-human (FIH) clinical trial of the company's proprietary, non-invasive sonodynamic drug-device therapy system for recurrent high-grade gliomas.
spot_img

By using this website you agree to accept Medical Device News Magazine Privacy Policy